NCT01742286 · OUTCOME
Pharmacokinetics (PK) Parameters: AUC0 - 24h & AUClast in Cycle 1 Day 1 - Dose Escalation Phase (Single Dose)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- hr*ng/mL
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- 0hr pre-dose, 2, 4, 6 & 24hrs post-dose
What was measured
Characterize single and multiple-dose PK of LDK378 in pediatric patients. AUC: Area under the plasma (serum, or blood) concentration versus time curve AUClast: Area under the concentration-time curve from time zero to the last measureable concentration time AUC0-24h: Area under the plasma concentration-time curve t=0-24 h
Analysis population: The PK analysis set (PAS) consisted of all patients who received at least one dose of ceritinib and had at least one evaluable PK sample.
Groups in this outcome
Fasted: Ceritinib 300 mg/m2
Participants in the fasted group who took 300 mg of ceritinib
Fasted: Ceritinib 450 mg/m2
Participants in the fasted group who took 450 mg of ceritinib
Fasted: Ceritinib 510 mg/m2
Participants in the fasted group who took 510 mg of ceritinib
Fasted: Ceritinib 560 mg/m2
Participants in the fasted group who took 560 mg of ceritinib
Fed: Ceritinib 320 mg/m2
Participants in the fed group who took 320 mg of ceritinib
Fed: Ceritinib 400 mg/m2
Participants in the fed group who took 400 mg of ceritinib
Fed: Ceritinib 500 mg/m2
Participants in the fed group who took 500 mg of ceritinib
| Group | Source count |
|---|---|
| Fasted: Ceritinib 300 mg/m2 | 5 |
| Fasted: Ceritinib 450 mg/m2 | 10 |
| Fasted: Ceritinib 510 mg/m2 | 3 |
| Fasted: Ceritinib 560 mg/m2 | 1 |
| Fed: Ceritinib 320 mg/m2 | 3 |
| Fed: Ceritinib 400 mg/m2 | 4 |
| Fed: Ceritinib 500 mg/m2 | 3 |
Reported measurements
AUC0-24h
| Group | Source count |
|---|---|
| Fasted: Ceritinib 300 mg/m2 | 4 |
| Fasted: Ceritinib 450 mg/m2 | 3 |
| Fasted: Ceritinib 510 mg/m2 | 2 |
| Fasted: Ceritinib 560 mg/m2 | 0 |
| Fed: Ceritinib 320 mg/m2 | 1 |
| Fed: Ceritinib 400 mg/m2 | 1 |
| Fed: Ceritinib 500 mg/m2 | 2 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Fasted: Ceritinib 300 mg/m2 | 3920 | 39.9 | Not reported | Not reported | Not reported |
| Fasted: Ceritinib 450 mg/m2 | 5220 | 58.0 | Not reported | Not reported | Not reported |
| Fasted: Ceritinib 510 mg/m2 | 8750 | 11.1 | Not reported | Not reported | Not reported |
| Fed: Ceritinib 320 mg/m2 | 5720 | 0.0 | Not reported | Not reported | Not reported |
| Fed: Ceritinib 400 mg/m2 | 7272 | 0.0 | Not reported | Not reported | Not reported |
| Fed: Ceritinib 500 mg/m2 | 4730 | 59.4 | Not reported | Not reported | Not reported |
AUClast
| Group | Source count |
|---|---|
| Fasted: Ceritinib 300 mg/m2 | 5 |
| Fasted: Ceritinib 450 mg/m2 | 9 |
| Fasted: Ceritinib 510 mg/m2 | 3 |
| Fasted: Ceritinib 560 mg/m2 | 1 |
| Fed: Ceritinib 320 mg/m2 | 3 |
| Fed: Ceritinib 400 mg/m2 | 4 |
| Fed: Ceritinib 500 mg/m2 | 3 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Fasted: Ceritinib 300 mg/m2 | 4260 | 39.3 | Not reported | Not reported | Not reported |
| Fasted: Ceritinib 450 mg/m2 | 4350 | 91.8 | Not reported | Not reported | Not reported |
| Fasted: Ceritinib 510 mg/m2 | 7670 | 24.5 | Not reported | Not reported | Not reported |
| Fasted: Ceritinib 560 mg/m2 | 4860 | 0.0 | Not reported | Not reported | Not reported |
| Fed: Ceritinib 320 mg/m2 | 3730 | 48.6 | Not reported | Not reported | Not reported |
| Fed: Ceritinib 400 mg/m2 | 5760 | 49.1 | Not reported | Not reported | Not reported |
| Fed: Ceritinib 500 mg/m2 | 4940 | 32.6 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 39.9
- value
- 3920
- group Id
- OG001
- spread
- 58.0
- value
- 5220
- group Id
- OG002
- spread
- 11.1
- value
- 8750
- group Id
- OG004
- spread
- 0.0
- value
- 5720
- group Id
- OG005
- spread
- 0.0
- value
- 7272
- group Id
- OG006
- spread
- 59.4
- value
- 4730
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 2
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 1
- group Id
- OG006
- value
- 2
- units
- Participants
- title
- AUC0-24h
- categories
- measurements
- group Id
- OG000
- spread
- 39.3
- value
- 4260
- group Id
- OG001
- spread
- 91.8
- value
- 4350
- group Id
- OG002
- spread
- 24.5
- value
- 7670
- group Id
- OG003
- spread
- 0.0
- value
- 4860
- group Id
- OG004
- spread
- 48.6
- value
- 3730
- group Id
- OG005
- spread
- 49.1
- value
- 5760
- group Id
- OG006
- spread
- 32.6
- value
- 4940
- denoms
- counts
- group Id
- OG000
- value
- 5
- group Id
- OG001
- value
- 9
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 3
- units
- Participants
- title
- AUClast
- denoms
- counts
- group Id
- OG000
- value
- 5
- group Id
- OG001
- value
- 10
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 3
- units
- Participants
- description
- Characterize single and multiple-dose PK of LDK378 in pediatric patients. AUC: Area under the plasma (serum, or blood) concentration versus time curve AUClast: Area under the concentration-time curve from time zero to the last measureable concentration time AUC0-24h: Area under the plasma concentration-time curve t=0-24 h
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Participants in the fasted group who took 300 mg of ceritinib
- id
- OG000
- title
- Fasted: Ceritinib 300 mg/m2
- description
- Participants in the fasted group who took 450 mg of ceritinib
- id
- OG001
- title
- Fasted: Ceritinib 450 mg/m2
- description
- Participants in the fasted group who took 510 mg of ceritinib
- id
- OG002
- title
- Fasted: Ceritinib 510 mg/m2
- description
- Participants in the fasted group who took 560 mg of ceritinib
- id
- OG003
- title
- Fasted: Ceritinib 560 mg/m2
- description
- Participants in the fed group who took 320 mg of ceritinib
- id
- OG004
- title
- Fed: Ceritinib 320 mg/m2
- description
- Participants in the fed group who took 400 mg of ceritinib
- id
- OG005
- title
- Fed: Ceritinib 400 mg/m2
- description
- Participants in the fed group who took 500 mg of ceritinib
- id
- OG006
- title
- Fed: Ceritinib 500 mg/m2
- param Type
- GEOMETRIC_MEAN
- population Description
- The PK analysis set (PAS) consisted of all patients who received at least one dose of ceritinib and had at least one evaluable PK sample.
- reporting Status
- POSTED
- time Frame
- 0hr pre-dose, 2, 4, 6 & 24hrs post-dose
- title
- Pharmacokinetics (PK) Parameters: AUC0 - 24h & AUClast in Cycle 1 Day 1 - Dose Escalation Phase (Single Dose)
- type
- SECONDARY
- unit Of Measure
- hr*ng/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle